checkAd

EQS-News Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies

Issuer: Mainz BioMed N.V. / Key word(s): Personnel
Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies

29.11.2022 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies

Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience as an in vitro diagnostics (IVD) industry leader

BERKELEY, US – MAINZ, Germany – November 29, 2022 — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Amy Levin, RAC, as Vice President of Regulatory Affairs.

In this role, Ms. Levin will be in charge of guiding the implementation and regulatory, clinical trial and quality initiatives that are related to in vitro diagnostics. She will contribute to key milestones for the FDA submission process for ColoAlert, the Company’s highly efficacious and easy-to-use DNA-based detection test for colorectal cancer (CRC). She will also be responsible for bridging the gap between business development and regulatory, clinical trial and quality teams to ensure the implementation of programs adhere to all regulatory specifications and meet customer expectations and goals.

“Ms. Levin is an outstanding addition to our executive team and is well known as a strategic thinker, methodical problem solver and inclusive people manager who is results-oriented,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “With these strong attributes and extensive professional experience, she will help drive our internal processes to support operational excellence as we execute our clinical trials and work toward FDA submission and approvals in the U.S.”

Ms. Levin has a successful track record of leading and collaborating with cross-functional teams and regulatory authorities to author, manage and review required reports of the U.S. Food and Drug Administration (FDA) and international regulatory submissions. Previously, she worked as Director, Roche Molecular Diagnostics (RMD) International Regulatory Affairs at RMD after serving in many roles with increasing leadership responsibilities within the company. While there, Ms. Levin drove the development and implementation of regulatory strategies for introducing new products in the marketplace and negotiated with worldwide health authorities to enable expeditious approval and importation of products across more than 50 countries. She has also held other regulatory positions at multiple Biotechnology companies in the San Francisco Bay area.

Seite 1 von 4



0 Kommentare
Nachrichtenquelle: EQS Group AG
 |  144   |   |   

Schreibe Deinen Kommentar

Disclaimer

EQS-News Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies Issuer: Mainz BioMed N.V. / Key word(s): Personnel Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies 29.11.2022 / 14:00 CET/CEST The issuer is solely responsible for the content of this …

Nachrichten des Autors

308 Leser
244 Leser
228 Leser
224 Leser
204 Leser
188 Leser
184 Leser
180 Leser
168 Leser
164 Leser
1032 Leser
880 Leser
756 Leser
704 Leser
692 Leser
536 Leser
516 Leser
496 Leser
476 Leser
476 Leser
1644 Leser
1240 Leser
1232 Leser
1056 Leser
1032 Leser
980 Leser
944 Leser
880 Leser
824 Leser
800 Leser
2389 Leser
2343 Leser
2237 Leser
2225 Leser
2172 Leser
2115 Leser
1997 Leser
1857 Leser
1713 Leser
1677 Leser